AC2 COMPARING PATIENT-REPORTED MEDICATION COMPLIANCE WITH ELECTRONICALLY MONITORED MEDICATION COMPLIANCE IN A 12-MONTH INTERNATIONAL REGISTRY  by Steffan, P et al.
230 Abstracts
intervention letters on the recurrence of exceptions, multiple
regression models were developed using prescriber-level mean
time (in days) between exceptions. In addition, the effect on
medical costs and utilization was measured for a subset of data
using a pre-post design with a control group. Pre-post periods
were deﬁned as 120 days before and after the date of interven-
tion letters dated between May 1 and August 31, 2003. Controls
were selected by matching to intervention cases using the propen-
sity score methods. Sensitivity analysis was performed using
varying time windows and bootstrap samples. Outcomes related
to PMPM inpatient admissions, emergency room visits, and
physician ofﬁce visits were analyzed. RESULTS: Of 51,214 pre-
scribers who had two or more exceptions during the 23-month
time period, 6233 (12%) were randomly selected to receive inter-
vention letters (ranging from one to 19). Model coefﬁcients indi-
cated that the time to exception was longer by 6.5 days (p <
0.001) as prescribers received additional intervention letters,
after adjusting for the number of exceptions, severity level, and
average patient age. There were no signiﬁcant differences in med-
ication costs from pre to post time periods, or between groups
(study vs. control). However, the study group had fewer PMPM
inpatient admissions and emergency room visits. CONCLU-
SIONS: Retrospective drug utilization review processes can have
a positive effect in delaying next exceptions for prescribers and
reducing utilization of health care services.
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OBJECTIVE: Budget impact analysis (BIA) evaluates ﬁnancial
impacts of new technologies; it provides valuable information to
decision-makers with a budget concern. This study proposes a
dynamic model to incorporate variations in patients mix and
drug prices over time in BIA. METHODS: The dynamic model
is an inhomogeneous Markov Chain model. It contains three
Markov states categorized by whether a patient’s illness was
treated with a generic drug, an existing brand-name drug, or the
new brand-name drug. At each cycle, the model modiﬁes the
patient cohort by accounting for newly diagnosed incident cases
and exiting cases due to cure or death. Also considered is a pos-
sible difference in the preference of treatment selection between
the current and newly diagnosed patients. We conducted BIA on
a simulated data using the Bayesian approach and presented the
results in a probabilistic plot similar to the cost-effectiveness
acceptability curve. A case study comparing the budget impact
of including versus excluding a new drug in a health plan was
used to demonstrate our method. The case study assumes the
perspective of a payer and a time frame of ﬁve years. RESULTS:
Results based on the simulated data showed that adding the 
new drug to the plan is associated with a budget increase in the
short run but would reduce the budget in the long run. The prob-
ability that including the new drug would increase in the budget
by 10% is 9%, 26% in a one- and two-year study timeframe,
and it becomes cost neutral in the ﬁve-year timeframe. CON-
CLUSIONS: The proposed model provides a powerful frame-
work to examine the time-varying parameters in BIA and
generates estimates that better reﬂect health care market in the
real world.
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OBJECTIVE: To capture patient compliance data on a pre-
scribed concomitant medication of an international product 
registry. The data needed to be collected in an accurate, timely,
non-burdensome, and cost-effective manner. METHODS:
Several patient compliance measurement options were consid-
ered but not selected including: physician ofﬁce surveys, tele-
phone surveys, and proxy responses. We chose the Medication
Electronic Monitoring Systems (MEMS), which is a standard
plastic vial, and a cap for the vial that contains a micro-
electronic circuit that records times when the cap is opened 
and closed. MEMS bottles and caps were given to participating
clinicians with speciﬁc instructions for distribution to registry
participants. MEMS were to be ﬁlled with a full 6-month pre-
scription of the concomitant medication and distributed to
patients at discharge. Patients were to be instructed to complete
the prescribed regimen and received instructions on the use and
purpose of the MEMS. They also were to receive written instruc-
tions on returning the MEMS to their clinician after 6 months.
The clinicians were to return the MEMS caps to a centralized
data processing center in the United States for analysis.
RESULTS: MEMS were distributed to 707 patients, by 43 physi-
cians, in 9 countries on 6 continents. The cost of distribution
(including devices and mailings) was approximately $100.00 per
patient. Delays in receiving MEMS caps from patients in a timely
manner were experienced, as were delays in receiving MEMS
caps from sites. Of the 240 MEMS devices administered, 26%
returned the cap for analysis and 24% of the MEMS caps yielded
analyzable data. CONCLUSION: Compared to other methods
of collecting compliance data on a large international scale,
MEMS provided a non-burdensome manner for collecting data.
However, the low return rate indicates that this process must be
monitored closely to maximize results, minimize costs and to
ensure that patient utilization does not vary.
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OBJECTIVE: This study compares two compliance measure-
ments, a telephone patient-reported survey and the Medication
Electronic Monitoring System (MEMS), for a 12-month inter-
national registry studying re-intervention rates for interventional
cardiology. METHODS: Patients were prescribed a 6-month
anti-platelet drug regimen upon discharge from the hospital.
Drug was supplied to all patients in a MEMS bottle, which con-
tained an electronic cap that recorded internally the date and
time the bottle was opened. At the end of six months, patients
were to return the empty bottle to their provider for analysis.
Patients included in this study were also contacted via telephone
quarterly to recall their medication compliance status. The agree-
ment between the two methods was evaluated using the weighted
Cohen’s kappa statistic (Kw). RESULTS: Of the 778 patients
enrolled in the registry, 707 were given MEMS devices, and of
those patients, 642 have reached the 6-month endpoint. A total
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of 136 patients returned their bottles and completed a telephone
survey. At Month 3, 98.53% of patients reported via telephone
that they continually took the drug; 0.74% had temporary inter-
ruptions of the drug; 0.74% discontinued the drug early. At
Month 3, MEMS data for those patients reported 44.85% with
continuous administration, 39.71% with temporary interrup-
tions, 15.44% discontinued early. Kw at Month 3 was 0.036
(95% CI = -0.018, 0.091). At Month 6, 83.82% of patients
reported via telephone that they completed taking the drug;
15.44% were still taking the drug; 0.74% discontinued the drug
early. At Month 6, MEMS data for those patients reported
63.24% completed, 0.74% were still taking, 36.03% discontin-
ued early. Kw at Month 6 was 0.069 (95% CI = -0.005, 0.144).
CONCLUSION: Based on the kappa statistic, there was little
agreement between the patient-reported and electronic methods
of measuring compliance. Patients reported being much more
compliant with their medication regimen than was reported by
MEMS.
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OBJECTIVES: A previous study conducted by the authors indi-
cated that calcium channel blockers, ACE inhibitors, beta block-
ers and diuretics were the four most commonly used therapeutic
classes of antihypertensives in a commercial HMO population.
The objective of this study was to compare adherence between
these four classes of antihypertensives. METHODS: This study
was a retrospective pharmacy claims database analysis. All
members evaluated had a diagnosis of hypertension, received at
least two prescriptions for an antihypertensive drug, and were
continuously enrolled during the one-year study period. The
average medication possession ratio (MPR) was used as a
primary adherence indicator. An analysis of covariance was con-
ducted to determine if differences in the mean MPR existed based
on the antihypertensive therapeutic class. Previous research in
this population indicated that age, units per day of the drug,
number of concurrent medications and total days supply were
signiﬁcant predictors of adherence. These factors were for in this
analysis. RESULTS: The average MPR was evaluated for 1637
members meeting the inclusion criteria. The average age of the
members was 52.85 year and 53.63% were female. The mean
(S.D.) MPR for the therapeutic classes were: ACE inhibitors
0.8626 (0.2370), beta-blockers 0.8534 (0.2288), calcium
channel blockers 0.8770 (0.2078), diuretics 0.8291 (0.2705).
The MPR were signiﬁcantly higher in members on calcium
channel blockers versus diuretics (mean difference = 0.0524,
95% CI = 0.0140–0.0907, p < 0.005) and ACE inhibitors versus
diuretics (mean difference = 0.0473, 95% CI = 0.0139–0.0808,
p < 0.005). There were no signiﬁcant differences in adherence
between the other classes of antihypertensives. CONCLUSIONS:
After controlling for signiﬁcant predictors of adherence, the
MPR for members on calcium channel blockers and ACE
inhibitors were signiﬁcantly higher than for those patients on
diuretics. These results may have implications for the effective-
ness of different therapeutic classes of antihypertensives in blood
pressure control.
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OBJECTIVE: The objective of this study was to quantify the
clinical and economic effects of non-adherence with triple
therapy in treatment-naïve HIV patients. METHODS: A
Markov model was developed to project quality-adjusted life
expectancy and direct medical costs for HIV patients (mean age
= 37 years) on an initial regimen of highly active antiretroviral
therapy (HAART) with efavirenz, lamivudine and extended
release stavudine given once daily. Each month, patients faced a
risk of transition to AIDS that was a function of viral load, CD4
count, and adherence to drug therapy. Patients were assumed to
change to another triple-therapy regimen if their viral load was
≥ 400 copies/mL or if they transitioned to AIDS. After four reg-
imens, patients followed the natural history of the disease. We
compared clinical and economic outcomes for two adherence
scenarios: “clinical trial” (representing ideal utilization observed
in clinical trials) and “typical” (based on observational studies
in actual practice). Costs were derived from the HIV/AIDS Costs
and Services Utilization Survey and average wholesale drug
prices. Future costs and QALYs were discounted 3%. RESULTS:
Mean discounted quality-adjusted life expectancy was 8.6 and
10.0 QALYs under the typical and clinical trial adherence sce-
narios, respectively. Lifetime direct medical costs in the typical
and trial scenarios were $295,000 and $336,000, respectively.
Compared with typical adherence, clinical trial adherence con-
ferred an average gain of 1.4 QALYs at an incremental cost of
$29,000 per QALY gained. Up to $1650 per patient per year
could be spent on an intervention to improve adherence from
typical to trial levels, and the incremental cost-effectiveness of
doing so would remain below $50,000 per QALY gained. CON-
CLUSIONS: Typical adherence with HAART reduces quality-
adjusted life expectancy by 14% compared to adherence levels
in clinical trials. Programs to improve adherence appear to be a
highly cost-effective use of resources.
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OBJECTIVES: Information on the comparative effectiveness of
different antipsychotic medications in a naturalistic setting is
important for clinicians and other health care decision-makers.
However, in long-term naturalistic studies, patients may remain
on treatment, switch, augment, or even stop treatment at any
time and for different reasons—making statements about the
causal effects of treatments difﬁcult. The objective of this
research was to assess several analytic strategies for comparing
treatment effectiveness in the presence of switching. METHODS:
Using data from a recently completed 1-year, randomized, natu-
ralistic, anti-psychotic cost-effectiveness trial for schizophrenia,
three different analysis strategies were utilized to compare the
effectiveness of treatments on schizophrenia symptom severity
(measured by BPRS total score): intent-to-treat, sub-setting by
